Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | PPARD | Q03181 | 4/20 | 0.54 |
| ▸ | PPARG | P37231 | 12/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384829 | 0.92 | CYP1A2 (0.65) | CYP1A2PPARAPPARGCPA1 | |
| SCHEMBL28181738 | 0.87 | CYP1A2 (0.77) | CYP1A2PPARAPPARGCPA1 | |
| SCHEMBL29865172 | 0.86 | PPARA (0.56) | CYP1A2PPARAPPARDPPARGEPHX2 | |
| SCHEMBL7333189 | 0.86 | PPARG (0.49) | CYP1A2PPARAPPARDPPARGEPHX2 | |
| SCHEMBL12493679 | 0.85 | CYP1A2 (0.55) | CYP1A2PPARAPPARGCPA1 | |
| SCHEMBL28662967 | 0.84 | PPARG (0.81) | PPARAPPARDPPARGEPHX2 | |
| SCHEMBL28313231 | 0.84 | EPHX2 (0.50) | CYP1A2PPARAPPARDPPARGEPHX2 | |
| SCHEMBL11529738 | 0.83 | CYP1A2 (0.59) | CYP1A2PPARAPPARDPPARGEPHX2 | |
| SCHEMBL3876493 | 0.83 | CYP1A2 (0.59) | CYP1A2PPARAPPARDPPARGEPHX2 | |
| SCHEMBL3661382 | 0.83 | CYP1A2 (0.59) | CYP1A2PPARAPPARDPPARGEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815935-B2 | Inhibitors of protein prenyltransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130102639-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-25 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | CYP1A2 3526/4885PPARA 1763/4885PPARD 1362/4885 |
| US-20130102639-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | RABGGTA, FNTA, RABGGTB | CYP1A2 3618/4885PPARA 2747/4885PPARD 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.